Skip to content

Hongene Biotech Seeks Pre-IPO Funds at $6 Billion Value, Sources Say

  • Shanghai-based firm could raise $400 million in pre-IPO round
  • Hongene is exploring Hong Kong IPO as soon as next year

Hongene Biotech Corp. is weighing a new funding round that could value the Chinese synthesis blocks and enzymes maker at about $6 billion, people familiar with the matter said.

The Shanghai-based company is working with advisers on the fundraising, which could raise about $400 million, said the people, who asked not to be identified as the information is private.